Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

Journal of Pediatrics

Volumn 134, Issue 4, 1999, Pages 413-421

  Smith, Arnold L ^{a,b,c,d,e,f,g,h,i,j,k,l}   Doershuk, Carl ^{a,b,c,d,e,f,g,h,i,j,k,l}   Goldmann, Donald ^{a,b,c,d,e,f,g,h,i,j,k,l}   Gore, Edward ^{a,b,c,d,e,f,g,h,i,j,k,l}   Hilman, Bettina ^{a,b,c,d,e,f,g,h,i,j,k,l}   Marks, Melvin ^{a,b,c,d,e,f,g,h,i,j,k,l}   Moss, Richard ^{a,b,c,d,e,f,g,h,i,j,k,l}   Ramsey, Bonnie ^{a,b,c,d,e,f,g,h,i,j,k,l}   Redding, Gregory ^{a,b,c,d,e,f,g,h,i,j,k,l}   Rubio, Thomas ^{a,b,c,d,e,f,g,h,i,j,k,l}   Williams Warren, Judy ^{a,b,c,d,e,f,g,h,i,j,k,l}   Wilmott, Robert ^{a,b,c,d,e,f,g,h,i,j,k,l}   Wilson, H David ^{a,b,c,d,e,f,g,h,i,j,k,l}   Yogev, Ram ^{a,b,c,d,e,f,g,h,i,j,k,l}  

^a University of Missouri   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^f Miller Children's at Long Beach Mem ^*  (United States)

^g LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

^h SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

ⁱ EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^k UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^l CHILDREN'S MEMORIAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; PLACEBO; TOBRAMYCIN;

ADOLESCENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPUTUM ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 0033498208     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70197-6     Document Type: Article

References (27)

1. 1. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
2. 2. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-21.
3. 3. Hyatt AC, Chippa BE, Kumor KM, Mellitis, Lietman PS, Rosenstein BJ. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. J Pediatr 1981;99:307-14.
4. 4. Penketh A, Hodson ME, Gaya H, Batten JC. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis. Thorax 1984; 39:299-304.
5. 5. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3:101-9.
6. 6. Leibovici L, Poznanski MPO, Drucker M, Samra Z, Konigsberger H, Pitlik SD. Monotherapy versus β-lactamaminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observation study. Antimicrob Agents Chemother 1997;41: 1127-33.
7. 7. Hoogkamp-Korstanje JA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. J Antimicrob Chemother 1983;12:175-83.
8. 8. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, Halsey NA. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988;4:201-4.
9. 9. McLaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P, Goldmann DA. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983;147:559-67.
10. 10. Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis-Moller A, Koch C. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazamine plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scand J Infect Dis 1986;13:133-7.
11. 11. DeBoeck K, Smet M, Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatr Pulmonol 1989;7:171-3.
12. 12. Wong K, Roberts MC, Owens L, Fife M, Smith AL. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol 1984;17:113-9.
13. 13. Gilligan PH, Gage PA, Bradshaw LM, Schidlow DV, DeCicco BT. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1985;22:5-8.
14. 14. Randomization procedures. In: Spilker B, editor. Guide to clinical trials. New York: Raven Press; 1985. p. 66-71.
15. 15. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:546-54.
16. 16. Taussig LM, Chernick V, Wood R, Farrell P, Mellins RB. Standardization of lung function testing in children. Proceedings and recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation. J Pediatr 1980;97:668-76.
17. 17. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-34.
18. 18. Aiken LR. Repeated measures and mixed designs ANOVA using SPSS. Malibu (CA): Pepperdine University; 1979. ED191906.
19. 19. Thornsberry C, Gavant T, Gerlach E. New developments in antimicrobial susceptibility. Cumitech 1997;6:1-13.
20. 20. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 3rd ed. Approved standard. Wayne (PA): NCCLS; 1993.
21. 21. Moellering RC, Wennersten C, Weinberg AN. Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med 1971;77: 821-8.
22. 22. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1988;7:171-6.
23. 23. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. Am J Med 1987;82:180-4.
24. 24. Beaudiy PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? J Pediatr 1980;97:144-7.
25. 25. Redding GJ, Restuccia R, Cotton EK, Brooks JG. Serial changes in pulmonary functions in children hospitalized with cystic fibrosis. Am Rev Respir Dis 1982;126:31-6.
26. 26. Cerny FJ, Cropp GJ, Bye MR. Hospital therapy improves exercise tolerance and lung function in cystic fibrosis. Am J Dis Child 1984;138:261-5.
27. 27. Michalsen H, Bergan T. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. Scand J Infect Dis 1981;29:92-7.